Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Shares, with no par value
-
Shares outstanding
-
51M
-
Number of holders
-
9
-
Total 13F shares, excl. options
-
1.83M
-
Shares change
-
+15.7K
-
Total reported value, excl. options
-
$5.63M
-
Value change
-
+$50.5K
-
Number of buys
-
3
-
Number of sells
-
-5
-
Price
-
$3.17
Significant Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) as of Q4 2024
10 filings reported holding EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value as of Q4 2024.
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) has 9 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.83M shares
of 51M outstanding shares and own 3.58% of the company stock.
Largest 10 shareholders include SCOTIA CAPITAL INC. (1.39M shares), Royal Bank of Canada (283K shares), BANK OF MONTREAL /CAN/ (56.8K shares), GOLDMAN SACHS GROUP INC (34.5K shares), UBS Group AG (28K shares), RAYMOND JAMES FINANCIAL INC (11.6K shares), 180 WEALTH ADVISORS, LLC (10.5K shares), MILLENNIUM MANAGEMENT LLC (10K shares), NATIONAL BANK OF CANADA /FI/ (43 shares), and TD Waterhouse Canada Inc. (0 shares).
This table shows the top 9 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.